GB1492383A - Therapeutic composition - Google Patents

Therapeutic composition

Info

Publication number
GB1492383A
GB1492383A GB1181374A GB1181374A GB1492383A GB 1492383 A GB1492383 A GB 1492383A GB 1181374 A GB1181374 A GB 1181374A GB 1181374 A GB1181374 A GB 1181374A GB 1492383 A GB1492383 A GB 1492383A
Authority
GB
United Kingdom
Prior art keywords
virus
immunoglobulins
viral
march
dry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB1181374A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seperic SA
Original Assignee
Seperic SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seperic SA filed Critical Seperic SA
Priority to GB1181374A priority Critical patent/GB1492383A/en
Priority to FR7506548A priority patent/FR2263784B1/fr
Priority to NL7502628A priority patent/NL7502628A/xx
Priority to DE19752511283 priority patent/DE2511283A1/de
Priority to BE154374A priority patent/BE826730A/xx
Publication of GB1492383A publication Critical patent/GB1492383A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
GB1181374A 1974-03-16 1974-03-16 Therapeutic composition Expired GB1492383A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB1181374A GB1492383A (en) 1974-03-16 1974-03-16 Therapeutic composition
FR7506548A FR2263784B1 (enExample) 1974-03-16 1975-03-03
NL7502628A NL7502628A (nl) 1974-03-16 1975-03-05 Werkwijze ter bereiding van therapeutische preparaten.
DE19752511283 DE2511283A1 (de) 1974-03-16 1975-03-14 Therapeutische zusammensetzung
BE154374A BE826730A (fr) 1974-03-16 1975-03-14 Medicaments a base de globulines anti-virales specifiques, notamment anti-herpetique, destines a l'usage externe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1181374A GB1492383A (en) 1974-03-16 1974-03-16 Therapeutic composition

Publications (1)

Publication Number Publication Date
GB1492383A true GB1492383A (en) 1977-11-16

Family

ID=9993165

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1181374A Expired GB1492383A (en) 1974-03-16 1974-03-16 Therapeutic composition

Country Status (5)

Country Link
BE (1) BE826730A (enExample)
DE (1) DE2511283A1 (enExample)
FR (1) FR2263784B1 (enExample)
GB (1) GB1492383A (enExample)
NL (1) NL7502628A (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2160771A (en) * 1984-06-28 1986-01-02 Lion Corp Composition for oral application
DE3417406A1 (de) * 1984-05-10 1986-01-02 Gödecke AG, 1000 Berlin Antiserum gegen hepatitis b-oberflaechenantigen aus schaf, pferd oder ziege und verfahren zu seiner herstellung
EP2248825A1 (en) * 2009-05-04 2010-11-10 Ribovax Biotechnologies SA Antigen binding fragments of an antibody for use in treating and diagnosing ocular diseases

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3417406A1 (de) * 1984-05-10 1986-01-02 Gödecke AG, 1000 Berlin Antiserum gegen hepatitis b-oberflaechenantigen aus schaf, pferd oder ziege und verfahren zu seiner herstellung
GB2160771A (en) * 1984-06-28 1986-01-02 Lion Corp Composition for oral application
US4714612A (en) * 1984-06-28 1987-12-22 Lion Corporation Composition for oral application
EP2248825A1 (en) * 2009-05-04 2010-11-10 Ribovax Biotechnologies SA Antigen binding fragments of an antibody for use in treating and diagnosing ocular diseases
WO2010128053A1 (en) * 2009-05-04 2010-11-11 Ribovax Biotechnologies Sa Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases
US8747856B2 (en) 2009-05-04 2014-06-10 Ribovax Biotechnologies S.A. Antigen binding fragments of an antibody for use in treating or diagnosing ocular diseases

Also Published As

Publication number Publication date
DE2511283A1 (de) 1975-09-18
FR2263784B1 (enExample) 1978-07-28
BE826730A (fr) 1975-06-30
NL7502628A (nl) 1975-09-18
FR2263784A1 (enExample) 1975-10-10

Similar Documents

Publication Publication Date Title
NO140301C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazo(5,1-f)-as-triaziner
CA1029303A (en) Method of contraception by the administration of stage-combination preparations
IL60185A (en) 6 beta,7 beta;15,16-dimethylene-1,4-androstadien-3-ones,process for their production and pharmaceutical preparations containing them
IE42340L (en) 11,12-secoprostaglandins
JPS5699412A (en) Rosemary aciddcontaining pharmaceutic product
DE3071977D1 (en) Peptides, process for their preparation, their pharmaceutical compositions and their intermediates
CA1016464A (en) Shampoo conditioner formulations
GB1492383A (en) Therapeutic composition
CA941381A (en) Derives de l'acide phenylacetique et leur application comme medicaments
ES415466A1 (es) Procedimiento para la obtencion de n - benzhidril - n' - p - hidroxibencilpiperazinas.
NO740614L (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-fenylaminoimidazolin (2)-forbindelser.
CA1029302A (en) Method of contraception by the administration of stage-combination preparations
EG11829A (en) The introduction of (o-ch3)group to olefin in it's gases stage
IE39885B1 (en) Diphenylimidazolidines and their pharmaceutical compositons
NO741309L (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive seco-prostaglandiner.
GB1177009A (en) Improvements in or relating to 9alpha, 11beta-Dichloro-Pregnane Compounds
NO142398C (no) Tiofenderivater for anvendelse som mellomprodukter ved fremstilling av terapeutisk aktive aminoalkylestere av alfa-substituert (3-tienyl)-eddiksyre
IE39714L (en) N-imidazolylethylcarbamates
GB1153767A (en) Improvements in or relating to Amitotic Therapeutic Composition Administrable by the Topical Route
GB1215152A (en) Biguanide derivatives and pharmaceutical preparations containing them
CA763405A (en) Process for the manufacture of pharmaceutical preparations in bead form
IE38289B1 (en) 2,7-bis 2-(4-azatricyclo-4,3.1.1. undec-4-yl ethoxy fluoren-9-one and congeners
NL7411472A (nl) Werkwijze ter bereiding van nieuwe farmaceuti- sche preparaten die als werkzaam bestanddeel 2-methyl-5-hydroxymethylthiazool bevatten en volgens deze werkwijze verkregen preparaten.
CA994267A (en) Process for the preparation of tuberculin active proteins and peptides
CA860670A (en) Vaporizer for delivery of vapor to facial area

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee